更新于：2024-12-14
Mivacurium Chloride
米库氯铵
更新于：2024-12-14
概要
基本信息
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1992-01-22), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C58H80ClN2O14 |
InChIKeyKFWHZSUNFAPZPW-FBIVYNMFSA-M |
CAS号106861-44-3 |
关联
17
项与 米库氯铵 相关的临床试验Muscle Relaxant Effect and Safety of Mivacurium Chloride and Succinylcholine for Bronchoscopy
Effect of mivacurium on tonsillar adenoidectomy in pediatric patients
Evaluation of Effectiveness of Two Different Doses of Mivacurium in Modified Rapid Sequence Intubation for Emergency Surgery ,Prospective Randomized Double Blind Study
100 项与 米库氯铵 相关的临床结果
登录后查看更多信息
100 项与 米库氯铵 相关的转化医学
登录后查看更多信息
100 项与 米库氯铵 相关的专利（医药）
登录后查看更多信息
735
项与 米库氯铵 相关的文献（医药）2024-10-04MEDICINE
A novel BCHE frameshift mutation in a Chinese woman with butyrylcholinesterase deficiency: A case report and literature review
Review
作者: Zeng, Jiantao ; Yang, Dan ; Zheng, Zhaobin ; Xia, Jun ; Dai, Tao
Rationale::
Congenital butyrylcholinesterase deficiency (BCHED) is a rare autosomal recessive genetic disorder caused by a pathogenic mutation in the BCHE gene. Patients with BCHED may experience prolonged apnea or even death after the application of drugs such as succinylcholine. We aimed to identify the genetic basis of disease in a patient presenting with butyrylcholinesterase deficiency in order to confirm the diagnosis, expand BCHE gene mutation spectrum, and elucidate potential genotype-phenotype associations to inform management.
Patient concerns::
A 51-year-old woman presented with “vague pain in the upper and middle abdomen.” Her serum cholinesterase level was 211 U/L (reference value 4000–13,000 U/L). Other laboratory findings were normal. Genetic analysis revealed compound heterozygous mutations in BCHE gene, which was considered pathogenic in this case.
Diagnoses::
The patient presented with low serum cholinesterase levels, which excluded common causes such as liver disease, drug toxicity, and chronic illness. Whole exon examination revealed compound heterozygous mutations in the BCHE gene; thus, the patient was diagnosed with congenital BCHED.
Interventions::
Gastroscopy without succinylcholine or mivacurium chloride was recommended. The gastroscopy results were “gastric polyps,” and gastroscopic “polypectomy” was performed. The patient was advised to avoid succinylcholine use.
Outcomes::
The patient’s serum cholinesterase level was reviewed 3 months later, and the result was 215 U/L. Double heterozygous mutations are the cause of BChE deficiency of this woman in this study, including a novel mutation NM_000055.4: c.666_669del (p.Phe223Glufs*38). A review of the literature reveals considerable variation in the hotspot variants of the BCHE gene across different populations. The Chinese population displays a higher prevalence of the silent type, which is more sensitive to anesthetics such as succinylcholine.
Lessons::
Clinical manifestations of congenital BCHED were not significant. This study avoided a potential anesthetic accident, and the novel variant enriched the BCHE gene mutation spectrum.
2024-08-01BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
Design, synthesis, and biological evaluation of new bis-benzylisoquinoline-based analogues as potential neuromuscular blocking agents
Article
作者: Song, Hao ; Chen, Chen ; Fu, Lin ; Ke, Bowen ; Liu, Xiaofeng ; Chen, Gang ; Qin, Yong ; Gan, Yu ; Zhao, Yi
Neuromuscular blocking agents (NMBAs) are widely used in anesthesia for intubation and surgical muscle relaxation. Novel atracurium and mivacurium derivatives were developed, with compounds 18c, 18d, and 29a showing mivacurium-like relaxation at 27.27 nmol/kg, and 15b, 15c, 15e, and 15h having a shorter duration at 272.7 nmol/kg. The structure-activity and configuration-activity relationships of these derivatives and 29a's binding to nicotinic acetylcholine receptors were analyzed through molecular docking. Rabbit trials showed 29a has a shorter duration compared to mivacurium. This suggests that linker properties, ammonium group substituents, and configuration are crucial for NMBA activity and duration, with compound 29a emerging as a potential ultra-short-acting NMBA.
2024-08-01ACTA ANAESTHESIOLOGICA SCANDINAVICA
Onset time, duration of action, and intubating conditions after mivacurium in elderly and younger patients
Article
作者: Rosager, Christine L. ; Dalsten, Helene ; Wadland, Sarah Sofie ; Kempff‐Andersen, Sebastian ; Creutzburg, Andreas ; Rasmussen, Lars S. ; Rosenkrantz, Oscar ; Vested, Matias
Abstract:
Background:
The neuromuscular blocking agent mivacurium can be used during anesthesia to facilitate tracheal intubation. Data on onset time, duration of action, and effect on intubating conditions in patients 80 years and older are however limited. We hypothesized that onset time and duration of action of mivacurium would be longer in elderly patients than in younger adults.
Methods:
This prospective observational study included 35 elderly (≥80 years) and 35 younger (18–40 years) patients. Induction of anesthesia comprised fentanyl 1–3 μg kg−1 and propofol 1.5–2.5 mg kg−1 and propofol and remifentanil for maintenance. Acceleromyography was used for monitoring neuromuscular blockade. The primary outcome was onset time defined as time from injection of mivacurium 0.2 mg kg−1 to a train‐of‐four (TOF) count of zero. Other outcomes included duration of action (time to TOF ratio ≥0.9), intubating conditions using the Fuchs‐Buder scale and the intubating difficulty scale (IDS), and occurrence of hoarseness and sore throat postoperatively.
Results:
No difference was found in onset time comparing elderly with younger patients; 219 s (SD 45) versus 203 s (SD 74) (difference: 16 s (95% CI: −45 to 14), p = .30). Duration of action was significantly longer in elderly patients compared with younger patients; 52 min (SD 17) versus 30 min (SD 8) (difference: 22 min [95% CI: 15 to 28], p < .001). No difference was found in the proportion of excellent intubating conditions (Fuchs‐Buder); 31/35 (89%) versus 26/35 (74%) (p = .12) or IDS score (p = .13). A larger proportion of younger patients reported sore throat 24 h postoperatively; 34% versus 0%, p = .0002. No difference was found in hoarseness.
Conclusion:
No difference in onset time of mivacurium 0.2 mg kg−1 was found comparing elderly and younger patients. However, elderly patients had significantly longer duration of action. No difference was found in intubating conditions.
100 项与 米库氯铵 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 妊娠剧吐 | 中国 | 2005-08-11 | |
| 麻醉 | 美国 | 1992-01-22 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 24 | (Moderate/Normal Surgical Block) | 鬱壓膚艱製選衊襯蓋積(廠夢鏇範觸顧觸憲夢獵) = 顧遞憲網獵餘鹹壓齋築 鏇窪選襯鏇鑰餘膚構鑰 (襯構廠夢蓋糧鑰鹽淵蓋, 願製襯願艱憲醖鏇繭顧 ~ 糧觸範製齋簾齋積蓋築) 更多 | - | 2016-10-17 | ||
(Deep Surgical Block) | 鬱壓膚艱製選衊襯蓋積(廠夢鏇範觸顧觸憲夢獵) = 繭襯醖積積範衊醖範廠 鏇窪選襯鏇鑰餘膚構鑰 (襯構廠夢蓋糧鑰鹽淵蓋, 蓋憲艱鏇鬱觸獵築齋糧 ~ 鑰蓋顧膚範獵艱製鹹醖) 更多 | ||||||
N/A | - | - | Mivacurium 50 microg/kg | 齋窪顧願鏇鹹糧簾窪顧(範選鹹齋夢鹹壓遞衊餘) = 衊範襯構鑰遞遞醖範構 廠齋簾選鹽網鬱獵獵顧 (選積願廠選選膚餘鬱夢, 82 ~ 127) 更多 | - | 2001-12-01 | |
Mivacurium 100 microg/kg | 齋窪顧願鏇鹹糧簾窪顧(範選鹹齋夢鹹壓遞衊餘) = 遞醖鹹廠積觸蓋觸鹹鏇 廠齋簾選鹽網鬱獵獵顧 (選積願廠選選膚餘鬱夢, 51 ~ 82) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用